- Home
- TYRA vs FFC Comparison
TYRA vs FFC Comparison
Compare TYRA & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- FFC
- Stock Information
- Founded
- TYRA 2018
- FFC 1983
- Country
- TYRA United States
- FFC United States
- Employees
- TYRA N/A
- FFC N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- FFC Trusts Except Educational Religious and Charitable
- Sector
- TYRA Health Care
- FFC Finance
- Exchange
- TYRA Nasdaq
- FFC Nasdaq
- Market Cap
- TYRA 819.3M
- FFC 757.4M
- IPO Year
- TYRA 2021
- FFC N/A
- Fundamental
- Price
- TYRA $15.91
- FFC $16.06
- Analyst Decision
- TYRA Strong Buy
- FFC
- Analyst Count
- TYRA 6
- FFC 0
- Target Price
- TYRA $30.50
- FFC N/A
- AVG Volume (30 Days)
- TYRA 261.4K
- FFC 164.1K
- Earning Date
- TYRA 03-18-2025
- FFC 01-01-0001
- Dividend Yield
- TYRA N/A
- FFC 6.79%
- EPS Growth
- TYRA N/A
- FFC N/A
- EPS
- TYRA N/A
- FFC N/A
- Revenue
- TYRA N/A
- FFC N/A
- Revenue This Year
- TYRA N/A
- FFC N/A
- Revenue Next Year
- TYRA N/A
- FFC N/A
- P/E Ratio
- TYRA N/A
- FFC N/A
- Revenue Growth
- TYRA N/A
- FFC N/A
- 52 Week Low
- TYRA $12.34
- FFC $11.90
- 52 Week High
- TYRA $29.60
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- TYRA 52.83
- FFC 62.50
- Support Level
- TYRA $15.75
- FFC $15.55
- Resistance Level
- TYRA $17.27
- FFC $15.88
- Average True Range (ATR)
- TYRA 0.91
- FFC 0.19
- MACD
- TYRA 0.20
- FFC 0.04
- Stochastic Oscillator
- TYRA 65.99
- FFC 97.22
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.